Press Releases

Year

September 22, 2021

Osmotica Pharmaceuticals plc to Present at Cantor Virtual Global Healthcare Conference 2021

BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief

September 2, 2021

Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference

BRIDGEWATER, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present

August 30, 2021

Osmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLC

-- Divestiture advances Company's transformation and emphasis on eye care and ocular aesthetics -- -- Proceeds of the sale will be used to retire a substantial portion of outstanding debt -- BRIDGEWATER, N.J., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”

August 16, 2021

Osmotica Pharmaceuticals plc Reports Second Quarter 2021 Results and Provides Business Update

Sale of legacy business to Alora Pharmaceuticals, LLC expected to close in third quarter 2021 Second quarter 2021 total Upneeq revenue of $11.5 million including a $10.0 million milestone payment from Santen Pharmaceutical Co., Ltd Upneeq prescriptions nearly doubled in the second quarter compared

August 12, 2021

Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021

BRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at

August 11, 2021

Osmotica Pharmaceuticals plc to Provide Second Quarter 2021 Business and Financial Update on August 16, 2021

BRIDGEWATER, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 second quarter financial results on Monday, August 16, 2021, after the

June 30, 2021

Osmotica Subsidiary RVL Pharmaceuticals, Focused on Eye Care and Ocular Aesthetics, Strengthens and Expands Leadership Team

BRIDGEWATER, NJ, June 30, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that J. Aaron Green will join the leadership team of RVL Pharmaceuticals, Inc.

June 25, 2021

Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC

Osmotica will receive a $110 million upfront cash payment, with the potential to receive up to $60 million in additional milestone payments Alora will acquire manufacturing operations in Marietta, Georgia in addition to legacy products Osmotica will retain the RVL Pharmaceuticals business focused

June 18, 2021

Osmotica Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting

BRIDGEWATER, N.J., June 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced results of the Company’s Annual General Meeting. At the Annual General Meeting of the Company held on June

May 25, 2021

Osmotica Pharmaceuticals plc to Present at Jefferies Virtual Healthcare Conference 2021

BRIDGEWATER, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn,

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 22

Investor Relations

News

Press Releases

Press Releases

Press Releases